Investigational Drug Information for BBI503
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug BBI503?
BBI503 is an investigational drug.
There have been 9 clinical trials for BBI503.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 13th 2017.
The most common disease conditions in clinical trials are Carcinoma, Hepatocellular, Neoplasms, and Carcinoma. The leading clinical trial sponsors are Boston Biomedical, Inc, Sumitomo Dainippon Pharma Oncology, Inc, and Sumitomo Dainippon Pharma Co., Ltd.
There are three US patents protecting this investigational drug and fifty-six international patents.
Summary for BBI503
| US Patents | 3 |
| International Patents | 56 |
| US Patent Applications | 38 |
| WIPO Patent Applications | 24 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 2 (2017-03-13) |
| Vendors | 7 |
Recent Clinical Trials for BBI503
| Title | Sponsor | Phase |
|---|---|---|
| A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors | Boston Biomedical, Inc | Phase 2 |
| A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors | Sumitomo Dainippon Pharma Oncology, Inc | Phase 2 |
| A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies | Boston Biomedical, Inc | Phase 2 |
Clinical Trial Summary for BBI503
Top disease conditions for BBI503
Top clinical trial sponsors for BBI503
US Patents for BBI503
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BBI503 | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| BBI503 | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| BBI503 | See Plans and Pricing | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BBI503
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BBI503 | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| BBI503 | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
| BBI503 | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
| BBI503 | European Patent Office | EP3452003 | 2036-05-05 | See Plans and Pricing |
| BBI503 | European Patent Office | EP3981392 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
